Eye Diseases Segment Held Largest Share of Application Segment in Cerebrospinal Fluid Management Market

According to our latest study on " Cerebrospinal Fluid Management Market Size and Forecast to 2030 – COVID-19 Impact and Global Analysis – by Type, Application, and Purchase Mode," the market was valued at US$ 15,793 million in 2022 and is expected to reach US$ 23,788.45 million by 2030. It is estimated to register a CAGR of 5.3% during 2022–2030. The report highlights the key factors and trends impacting the market and focuses on prominent players and their strategies.

Cerebrospinal fluid is a fluid found in the brain and spinal cord that safeguards the brain and spinal cord mechanically and immunologically. Various management devices such as CSF shunts and CSF drainage systems are used to manage the flow of CSF in the body, away from the ventricles in a controlled manner, thus preventing abnormal accumulation of CSF or hydrocephalus. . The factors driving the market include increasing incidences of CSF leak and growing developments for CSF management products. However, the risk associated with CSF shunts hinders the market growth.

The growing demand for better treatment modalities has resulted in various product developments in the last few decades. A few of the examples of recent product developments in the CSF management market are mentioned below.

•In September 2022, Anuncia Medical Inc received US Food and Drug Administration (FDA) approval for its ReFlow System Mini for the treatment of patients with hydrocephalus and other cerebrospinal fluid disorders that require shunting. ReFlow System Mini noninvasively facilitates a flush of ventricular catheters to restore, increase, or maintain CSF flow in a shunt.

•In March 2021, the FDA granted a breakthrough device designation for the ReFlow System of Anuncia for CSF management. The device is designed to treat CSF disorders such as hydrocephalus, which require shunting. ReFlow system can be used in homecare settings and in clinics for prophylactic flushing that is performed noninvasively to potentially prevent CSF blockages.

•In June 2020, the FDA granted Breakthrough Device Designation to the FlowSense wireless, noninvasive flow sensor offered by Rhaeos, Inc. The product is designed to rapidly monitor ventricular shunt function in patients with excess cerebrospinal fluid caused by hydrocephalus.

Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others. In 2022, the hospitals segment held the largest share of the market, by end user. Moreover, same segment is expected to grow at the fastest rate during the coming years. Hospitals serve as primary healthcare centers by employing qualified medical and healthcare personnel to offer convenient services and the best care to patients. CSF management services offered by a majority of hospitals are covered under insurance policies, which encourages patients to receive treatment at hospitals. Also, post-operative care is offered in the best possible manner to prevent further complications. As all the services are offered under one roof, hospitals are largely preferred across the world. Moreover, the availability of multiple hospitals in the countries allows patients to choose from different options for their treatments. Many hospitals worldwide are focusing on the introduction of neurological services to offer effective treatment outcomes for a range of neurological diseases.

Medtronic plc; Integra LifeSciences Corporation; B. Braun Melsungen AG; Argi Group Health Services Ltd Sti; Sophysa SA; BeckerSmith Medical; Biometri, Spiegelberg GmbH & Co; Moller Medical GmbH, and Delta Surgical are among the key players operating in the global cerebrospinal fluid management market.

The report segments the global cerebrospinal fluid management market as follows:

The cerebrospinal fluid management market is segmented based on product and end user. By product, the cerebrospinal fluid management market is bifurcated into CSF shunts and CSF drainage systems. CSF shunts is further segmented into ventriculoperitoneal shunts, ventriculoatrial shunts, ventriculopleural shunts, and lumboperitoneal shunts. CSF drainage systems is further bifurcated into external ventricular drainage (EVD) systems and lumbar drainage (LD) systems. Based on end user, the cerebrospinal fluid management market is segment into hospitals, clinics, ambulatory surgical centers, and others. Geographically, the cerebrospinal fluid management market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com